Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study

ConclusionsConsistent with the known hypercoagulability in severe COVID-19, the use of apixaban, enoxaparin, or aspirin was independently associated with lower mortality in critically ill COVID-19 patients.Editor ’s PerspectiveWhat We Already Know about This TopicWhile the treatment of critically ill COVID-19 patients has improved, mortality rates remain highWhat This Article Tells Us That Is NewIn a retrospective cohort consisting of 2,070 critically ill COVID-19 patients treated in six hospitals, multivariable regression analysis showed lower in-hospital mortality associated with apixaban, aspirin, or enoxaparin treatmentPropensity score –matching analyses demonstrated lower mortality for patients receiving apixaban (27% [96 of 360]vs. 37% [133 of 360]), aspirin (26% [121 of 473]vs. 30% [140 of 473]), or enoxaparin (25% [87 of 347)vs. 34% [117 of 347]) compared to matched controls
Source: Anesthesiology - Category: Anesthesiology Source Type: research